Related references
Note: Only part of the references are listed.Genome-Wide Expression Analysis of Middle Eastern Colorectal Cancer Reveals FOXM1 as a Novel Target for Cancer Therapy
Shahab Uddin et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
FoxM1: A Master Regulator of Tumor Metastasis
Pradip Raychaudhuri et al.
CANCER RESEARCH (2011)
被撤回的出版物: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors (Retracted article. See vol. 158, pg. 607, 2016)
Aamir Ahmad et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
FoxM1 Mediates Resistance to Herceptin and Paclitaxel
Janai R. Carr et al.
CANCER RESEARCH (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells
Jimmy M. -M. Kwok et al.
MOLECULAR CANCER RESEARCH (2010)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
Critical Role and Regulation of Transcription Factor FoxM1 in Human Gastric Cancer Angiogenesis and Progression
Qiang Li et al.
CANCER RESEARCH (2009)
FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27kip1
Jiping Zeng et al.
JOURNAL OF PATHOLOGY (2009)
FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness
I-Ching Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis
D. W. Chan et al.
JOURNAL OF PATHOLOGY (2008)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
被撤回的出版物: Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells (Retracted article. See vol. 78, pg. 5470, 2018)
Zhiwei Wang et al.
CANCER RESEARCH (2007)
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 study group
Jaffer A. Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
Anna D. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells
MG Liu et al.
CANCER RESEARCH (2006)
The forkhead box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer
IM Kim et al.
CANCER RESEARCH (2006)
Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice
TV Kalin et al.
CANCER RESEARCH (2006)
Forkhead box m1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase
IC Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
JA Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe
DR Wonsey et al.
CANCER RESEARCH (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
FoxM1 is required for execution of the mitotic programme and chromosome stability
J Laoukili et al.
NATURE CELL BIOLOGY (2005)
Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor
VV Kalinichenko et al.
GENES & DEVELOPMENT (2004)
Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells
R Balachandran et al.
ONCOGENE (2003)
Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer
K Fujitani et al.
ONCOLOGY (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
